Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Liquid chromatogram-tandem mass spectrum method for detecting pitavastatin in human plasma, and application to clinical pharmacokinetic research

A technology of pitavastatin and liquid chromatography, which is applied in the field of liquid chromatography-tandem mass spectrometry for the detection of pitavastatin in human plasma, can solve the problems of complex pretreatment, drug instability, and long analysis period of biological samples, and achieve detection Fast, less interference, meet the detection effect

Active Publication Date: 2017-09-08
苏州海科医药技术有限公司
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] In order to solve the above technical problems, in order to establish a simple, reliable, high-throughput, condition-controllable extraction and detection of protein precipitation method, and use deuterated internal standard as calibration for the determination of the plasma concentration of pitavastatin in human plasma, To solve the problems of long analysis period of biological samples, complex pretreatment, unstable drugs, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Liquid chromatogram-tandem mass spectrum method for detecting pitavastatin in human plasma, and application to clinical pharmacokinetic research
  • Liquid chromatogram-tandem mass spectrum method for detecting pitavastatin in human plasma, and application to clinical pharmacokinetic research
  • Liquid chromatogram-tandem mass spectrum method for detecting pitavastatin in human plasma, and application to clinical pharmacokinetic research

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0051] Abbreviation

[0052]

[0053] 1 material

[0054] 1.1 Instrument

[0055] Chromatograph: LC-30AD fast liquid chromatography system, Shimadzu Corporation, Japan.

[0056] Mass spectrometer: Model 6500 triple quadrupole tandem mass spectrometer equipped with an electrospray ionization source (Turbo Ion Spray) from Sciex, Canada.

[0057] Software used for data processing: Analyst (version 1.6.3), Sciex, Canada.

[0058] Centrifuge: HerμLe Z2326K desktop centrifuge, Germany Hermer Company.

[0059] Analytical balance: CD225D analytical balance, Beijing Sartorius Instrument Co., Ltd.

[0060] 1.2 Reference substances and reagents

[0061] Pitavastatin calcium (purity, 88.2%) was provided by Shenzhen Xinlitai Pharmaceutical Co., Ltd., d 4 - Pitavastatin calcium (purity, 98.6%) was purchased from Toronto Research Chemicals, Canada. Methanol, acetonitrile, and ammonium acetate (HPLC grade) were purchased from Sigma, USA. Deionized water (18.2mΩ, TOC≤50ppb) was prep...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a liquid chromatogram-tandem mass spectrum method for detecting pitavastatin in human plasma, and application to clinical pharmacokinetic research. The invention provides a method for detecting pitavastatin concentration of plasma. By the method, the pitavastatin concentration of the plasma can be analyzed through LC-MS / MS. According to the method provided by the invention, a protein precipitate pretreatment method is preferably adopted, deuterated pitavastatin serves as internal standard, Eclipse Plus Phenyl-Hexyl column isocratic elution is adopted, and electrospray ionization (ESI) tandem mass spectrum detection is adopted. By adoption of the method provided by the invention, the extraction and recovery rate of the plasma sample is 93 percent or higher and is not influenced by matrix effect, the stability of the pitavastatin is inspected by counting the pitavastatin concentration RSD% before pretreatment, the accuracy of the measured data is guaranteed, the method is high in specificity and selectivity, high in sensitivity, rapid in detection and small in use amount, and simple, reliable, high-flux and condition-controllable clinical mass-batch sample analysis requirements are met. The specificity, the stability and the like of the method provided by the invention are verified, and the method can be used for evaluating the bioequivalence of various dosage forms of pitavastatin successfully.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to a liquid chromatography-tandem mass spectrometry method for detecting pitavastatin in human plasma and an application thereof. Background technique [0002] Pitavastatin (Pitavastatin, PTV) structural formula is as follows figure 1 As shown, it is a third-generation statin drug jointly developed by Nissan Chemical Industry Co., Ltd. and Kowa Co., Ltd., which is a kind of inhibitor of hydroxymethylglutaryl coenzyme A (HMG-CoA), which can effectively reduce blood lipid levels. It is clinically used to treat primary hyperlipidemia and mixed dyslipidemia. PTV exists mainly in the form of the original form in the human body, just like other statin compounds. The PTV structure contains a hydroxycarboxylic acid structure, which can be dehydrated and ring-closed to form a pitavastatin lactone structure both in vivo and in vitro. Since pitavastatin lactone is easily hyd...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N30/02G01N30/06
CPCG01N30/02G01N30/06
Inventor 陈云辉钟勘杨勇
Owner 苏州海科医药技术有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products